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Legends for Supplementary Figures
Supplementary Figure 1. Treatment with CpG causes a reduction of Treg within the CD4 T 
cell population and an increase of CD8+ tumor-infiltrating cells. (a) The CT26 tumors 
described in Figure 1b were stained for CD4 and infiltrating cells were counted by 
fluorescence microscopy. The FoxP3/CD4 ratio was determined. (b) The proportion of 
FoxP3+ cells within tumor-infiltrating CD3+CD4+ T cells was determined by flow cytometry.
(c) Mice bearing CT26 tumors with an average size of 60 mm2 were treated peritumorally 
with a single dose of 100g CpG and the number of FoxP3+ and CD8+ cells per mg tumor 
tissue, the percentage of FoxP3+ cells within CD3+ cells and the CD8/FoxP3 ratio were 
determined by flow cytometry four and eight days after CpG treatment. Data are presented 
as in Figure 1c. P values were calculated relative to untreated mice (*p < 0.05; **p < 0.01; ns, 
not significant).
Supplementary Figure 2. CpG-induced suppression of Treg infiltration in different mouse 
tumor models. Subcutaneous B16 or EG-7 tumors were induced in C57BL/6 mice. (a) Mice 
bearing B16 tumors (average size 60 mm2) were treated twice at a two-day interval with CpG 
(n = 7) or remained untreated (n = 7). Two days after the last injection of CpG, tumor-
infiltrating FoxP3+ and CD3+ cells were stained on frozen tissue sections and counted in 
each sample. Data are presented as in Figure 1. (b) EG-7 tumor-bearing mice (average 
tumor size 60 mm2) were treated three times with CpG at two-days intervals (n = 5) or 
remained untreated (n = 5). Infiltrating T cells were analyzed as in (a). No evaluation of CD3 
was performed in the EG-7 model because of CD3 auto-expression by the tumor cells. Error 
bars indicate SEM. P values were calculated relative to untreated mice (*p < 0.05; ***p < 
0.001).
Supplementary Figure 3. Correlation (corr) of intratumoral FoxP3+ cells and CCL22 levels 
in CT26 tumors from untreated mice (same mice as in Figure 1b and d). CT26 tumors were 
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implanted as described in Fig. 1 and analyzed for infiltration by FoxP3+ cells and 
intratumoral CCL22. Each data point represents one tumor sample of one individual mouse.
Correlation was calculated using Pearson’s correlation coefficient.
Supplementary Figure 4. Inducible secretion of CCL22 by CT26-CCL22dox cells. (a) One 
day after the addition of 2 g/ml doxycycline to the supernatant of cultured CT26-CCL22dox
tumor cells, CCL22 induction was measured in the supernatant by ELISA. (b) BALB/c mice 
were inoculated with subcutaneous CT26-CCL22dox tumors and fed with a normal (n = 7) or 
doxycycline-containing (n = 7) diet. 30 days after tumor inoculation, CT26-CCL22dox tumors 
were collected and CCL22 levels in the homogenates were measured via ELISA. The 
proportion of infiltrating CD4+FoxP3+ cells was determined by flow cytometry. Error bars 
indicate SEM. P values were calculated relative to untreated cells or mice, respectively (*p < 
0.05; **p < 0.01).
Supplementary Figure 5. CCL22 secretion of human tumor cell lines upon IFN-J
stimulation. Different human tumor cell lines were cultured for three days either untreated or 
treated with IFN-J. CCL22 levels in the supernatants were determined by ELISA. Error bars 
indicate SEM. P values were calculated relative to untreated cells (*p <0.05; **p < 0.01).
Supplementary Figure 6. Type I interferon is a key mediator in the process of CCL22 
suppression and tumor regression. (a) Sucutaneous B16 tumors were induced in C57BL/6 
(n=10) or type I interferon receptor-deficient (IFNAR) mice (n=10). At day 12 after tumor 
induction, mice of both groups were either treated with 250g poly(I:C) or remained
untreated (n = 6 per group). Tumor size was measured every second day and expressed as 
mm2. (b) CT26 or Panc02 tumor-bearing mice were injected with 3 x 105 U IFN-Į or PBS.
Four days after treatment intratumoral FoxP3+ cell numbers and CCL22 protein expression 
was analyzed by flow cytometry and ELISA respectively. Error bars indicate SEM. P values 
of poly (I:C)-treated mice were calculated to the corresponding untreated animals (**p < 0.01; 
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ns, not significant).
Supplementary Figure 7. Efficacy of anti-tumor treatment with CpG is dependent on an 
CD8+ T cell response. (a) Mice with CpG-mediated complete tumor regression were re-
challenged with a lethal dose of CT26 (0.25 x 106) and tumor growth was measured every 
second day. Tumor growth was compared to mice without previous tumor encounter injected 
with the same amount of CT26 cells. (b) Intratumoral CD8+ T cells were isolated from CpG-
or PBS-treated CT26 tumor-bearing mice 4 days after treatment. Cells were incubated ex
vivo for 4h with AH1 peptide and intracellular IFN-Ȗ expression was measured by flow 
cytometry. Error bars indicate SEM. P value was calculated relative to cells isolated from
untreated mice (*p < 0.05)
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Supplementary Figure 1
27.955.0
0
10
%
 F
ox
P
3+
 in
 C
D
3+
C
D
4+
20
30
40
50
0.4
0.3
0.2
0.1
0
*
**
Gate on CD3+CD4+ cells Untreated
A
C
B
CpG p.t.
Fo
xP
3/
C
D
4 
ra
tio
C
D
8/
Fo
xP
3 
ra
tio
C
D
8/
Fo
xP
3 
ra
tio
Untreated
CpG p.t.
Untreated
CpG p.t.
CpG c.l.
Untreated CpG p.t.
FoxP3
C
D
4
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
Day 4 post CpG treatment
Day 8 post CpG treatment
0
5
10
15
*
0
5
10
15
20
*
*
0
10
20
30 ns
ns
ns
0
5
10
15
20
25
**
**
 %
Fo
xP
3+
 o
f 
in
tra
tu
m
or
al
 C
D
3+
 %
Fo
xP
3+
 o
f 
in
tra
tu
m
or
al
 C
D
3+
C
D
4+
Fo
xP
3+
 c
el
ls
 
pe
r m
g 
tu
m
or
 
C
D
4+
Fo
xP
3+
 c
el
ls
 
pe
r m
g 
tu
m
or
 
0
1
2
3
4
5
0
1
2
0
20
40
60
80
C
D
3+
C
D
8+
 c
el
ls
pe
r m
g 
tu
m
or
C
D
3+
C
D
8+
 c
el
ls
pe
r m
g 
tu
m
or
0
5
10
15
4
ht
tp
://
do
c.
re
ro
.c
h
Supplementary Figure 2
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Supplementary Figure 4
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Supplementary Figure 6
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